Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2005 2
2010 1
2012 1
2013 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
VRX-496(VIRxSYS).
Morris KV. Morris KV. Curr Opin Investig Drugs. 2005 Feb;6(2):209-15. Curr Opin Investig Drugs. 2005. PMID: 15751745 Review.
VIRxSYS is developing VRX-496, a lentiviral HIV-based vector encoding anti-HIV antisense envelope sequences, as a potential gene therapy for HIV infection. ...
VIRxSYS is developing VRX-496, a lentiviral HIV-based vector encoding anti-HIV antisense envelope sequences, as a potential ge …
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.
Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L, Kalos M, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, Slepushkin V, Veloso E, Mackley A, Hwang WT, Aberra F, Zhan J, Boyer J, Collman RG, Bushman FD, Levine BL, June CH. Tebas P, et al. Blood. 2013 Feb 28;121(9):1524-33. doi: 10.1182/blood-2012-07-447250. Epub 2012 Dec 20. Blood. 2013. PMID: 23264589 Free PMC article. Clinical Trial.
We report the safety and tolerability of 87 infusions of lentiviral vector-modified autologous CD4 T cells (VRX496-T; trade name, Lexgenleucel-T) in 17 HIV patients with well-controlled viremia. ...This is the first demonstration that gene-modified cel …
We report the safety and tolerability of 87 infusions of lentiviral vector-modified autologous CD4 T cells (VRX496-T; trade na …
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. Bayés M, et al. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. Methods Find Exp Clin Pharmacol. 2005. PMID: 16082422
John's Wort extract, stavudine; Tacrolimus, tadalafil, tafenoquine succinate, talaglumetad, tanomastat, taxus, tegaserod maleate, telithromycin, tempol, tenofovir, tenofovir disoproxil fumarate, testosterone enanthate, TH-9507, thalidomide, tigecycline, timolol maleate, tiotropiu …
John's Wort extract, stavudine; Tacrolimus, tadalafil, tafenoquine succinate, talaglumetad, tanomastat, taxus, tegaserod maleate, telithromy …
American Society of Gene & Cell Therapy--13th Annual Meeting.
Romano G. Romano G. IDrugs. 2010 Jul;13(7):444-7. IDrugs. 2010. PMID: 20582867
Investigational drugs discussed include the TAG vaccine and INGN-007 (both Gradalis Inc), AdCD40L (Uppsala University), Ad5-SSTR/TK-RGD (University of Alabama at Birmingham), CGTG-102 (Oncos Therapeutics Ltd) and lexgenleucel-T (VIRxSYS Corp)....
Investigational drugs discussed include the TAG vaccine and INGN-007 (both Gradalis Inc), AdCD40L (Uppsala University), Ad5-SSTR/TK-RGD (Uni …
Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects.
MacGregor RR. MacGregor RR. Hum Gene Ther. 2001 Nov 1;12(16):2028-9. Hum Gene Ther. 2001. PMID: 11727736 Clinical Trial.
Expression of the anti-HIV antisense env from a HIV vector transcript would target wt-HIV RNA and destroy it, and hence, decrease productive HIV replication from CD4 T cells. The clinical goal for this treatment approach is to decrease viral loads and promote CD4 T
Expression of the anti-HIV antisense env from a HIV vector transcript would target wt-HIV RNA and destroy it, and hence, decrease productive …